EU approves AstraZeneca’s COVID-19 vaccine as booster shot
- Antibiotics Unveiled as Potential Life Extenders Aiding Healthier Aging
- NK Cells: Unveiling a Multifaceted Medical Marvel for Stroke Recovery and Beyond
- Japan’s Shift to Regular COVID-19 Vaccination for Elderly
- Active Monitoring vs. Surgery for Moderate Cervical Lesions
- Probiotics Linked to Immune Suppression and Tumor Growth
- FDA Investigates T-Cell Malignancy Risk in CAR-T Cell Therapy
EU approves AstraZeneca’s COVID-19 vaccine as booster shot
- FDA Investigates T-Cell Malignancy Risk in CAR-T Cell Therapy
- WHO Requests More Information from China on Pediatric Clustered Pneumonia
- First Chinese PD-1 Cancer Drug 30 Times More Expensive in U.S. than in China
- Cardiovascular Diseases Linked to COVID-19 Infections
- What is the difference between dopamine and dobutamine?
- How long can the patient live after heart stent surgery?
EU approves AstraZeneca’s COVID-19 vaccine as booster shot.
On May 23, British/Swedish multinational pharmaceutical company AstraZeneca said that its COVID-19 vaccine Vaxzevria has been approved by the European Medicines Agency (EMA) as a booster vaccine for adults.
Last Thursday, AstraZeneca’s COVID-19 vaccine booster (clinical trial data) received a positive assessment from the European Committee for Medicinal Products for Human Use (CHMP).
AstraZeneca said in a statement on Monday that the company’s COVID-19 vaccine can be used as a booster shot for the first two doses of the Vaxzevria COVID-19 vaccine, as well as other messenger ribonucleic acid (mRNA) produced by companies such as Pfizer/BioNTech or Moderna. A booster shot of the COVID-19 vaccine.
The European Medicines Agency concluded that there was “substantial evidence” of an enhanced immune response following the administration of the Vaxzevria vaccine co-developed with the Oxford conference as a third booster dose, the statement said.
Despite a 40% drop in sales in Europe, where the outbreak is under control following the vaccination, AstraZeneca announced last month that sales of Vaxzevria quadrupled to US$1.15 billion in the first quarter. .
But AstraZeneca also warned in April that COVID-19 revenue, including Vaxzevria, would decline this year as the health crisis subsides.
Information about Vaxzevria
Vaxzevria is a vaccine for preventing coronavirus disease 2019 (COVID-19) in people aged 18 years and older. COVID-19 is caused by SARS-CoV-2 virus.
Vaxzevria is made up of another virus (of the adenovirus family) that has been modified to contain the gene for making a protein from SARS-CoV-2.
Vaxzevria does not contain the virus itself and cannot cause COVID-19.
Detailed information about this vaccine is available in the product information, which includes the package leaflet.
(source:internet, reference only)
Disclaimer of medicaltrend.org
